SYNGAP1 Legislative Advocacy
![display_BIPC_Logo display_BIPC_Logo](https://a0pd0b.a2cdn1.secureserver.net/wp-content/uploads/2022/08/display_BIPC_Logo-300x234.jpg)
Buchanan, Ingersoll, and Rooney PC, on behalf of the SYNGAP1 Foundation, will provide pro bono services to develop and execute a government relations strategy aligning SYNGAP1's agenda with the current environment in Washington, D.C.
![Image Image](https://a0pd0b.a2cdn1.secureserver.net/wp-content/uploads/2022/08/Image-300x216.jpeg)
![CC-Badge-Transparent--300x192 CC-Badge-Transparent--300x192](https://a0pd0b.a2cdn1.secureserver.net/wp-content/uploads/2022/08/CC-Badge-Transparent-300x192-1.png)
![Monica - Speaking Monica - Speaking](https://a0pd0b.a2cdn1.secureserver.net/wp-content/uploads/2022/08/Monica-Speaking.jpeg)
![PRV McCaul Congressional record PRV McCaul Congressional record](https://a0pd0b.a2cdn1.secureserver.net/wp-content/uploads/2022/08/PRV-McCaul-Congressional-record.png)
HON. MICHAEL T. McCAUL
of Texas in the House of Representatives
Thursday, July 14, 2016
This program is a crucial incentive--in addition to the Orphan Drug Act--for drug manufacturers to invest significantly in developing therapies for rare pediatric diseases, including pediatric cancers and lysosomal storage disorders.